1Bertoli AM, Vila I.M, Apte M, et al. Systemic lupus erythematosus in a muhiethnic US cohort I.UMINA Lh anacmia as a pre dictor of disease activity and damage accrual. Rheumatology (Oxford), 2007, 46:1471.
2Sultan S, Begum S, Isenberg D. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology, 2003, 42 : 230.
3Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus, 2006, 15:223.
4Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus, 2005, 14: 85.
5Wang SW, Cheng TT Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report. Lupus, 2005, 14:483.
6Avina-Zubieta JA, Galindo-Rodriguez G, Robledo I, et al. Longterm effectiveness of danazol corticosteroids and cytotoxic drugs in the treatmentof hematologic manifestations of systemic lupus erythematosus. Lupus, 2003, 12: 52.
7Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thromboeytopenia assoeiated with systemic lupus erythematosus; 59 eases. J Rheumatol, 2002, 29; 75.
8Vila LM, Alarcon GS, McGwin G Jr, et al. Lumina Study Group. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum, 2006, 55 :799.
9Yu HH, Wang LC, Lee JH, et al. l.ymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatrie systemic lupus erythematosus patients. Rheumatology , 2007, 46:1492.
1Vila LM, Alarcon GS, MeGwin G Jr, et al. Lumina Study Group: systemic lupus erythematosus in a multiethnic US cohort, XXXVH: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum, 2006, 55: 799-806.
2Ng WL, Chu CM, Wu AK, et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. Q J Med, 2006, 99: 37-47.
3Yu HH, Wang LC, Lee JH, et al.Lymphopenia is associated with neuropsychiatrie manifestations and disease activity in paediatric systemic lupus erythematosus patients. Rheumatology, 2007, 46: 1492-1494.
4Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus: clinical,diagnostic,and prognostic significance. Arthritis Rheum, 1978, 21: 295-305.
5Denburg SD, Behmann SA, Carbotte RM, et al. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum, 1994, 37: 369-375.
6Drenkard C, Villa AR, Reyes E, et al.Vasculitis in systemic lupus erythematosus. Lupus, 1997, 6: 235-242.
7Utsinger PD. Relationship of lymphocytotoxic antibodies to lymphopenia and parameters of disease activity in systermic lupus erythematosus. J Rheumatol, 1976, 3: 175-185.
8Mirzayan M J, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus.Rheumatology (Oxford), 2000, 39: 1316-1319.
9Osman C, Swank AJ. Lymphocytotoxic antibodies in SLE: a review of the literature. Clin Rheumatol ,1994, 13: 21-27.
10Winfield JB, Mimura T. Pathogenetic significance of anti-lymphocyte autoantibodies in systemic lupus erythematosus. Clan Immunol Immunopathol, 1992, 63:13-16.
